Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Novartis | Contract Pharma

What are you searching for?

Sign in

Financial Report: Novartis

Revenue down 2% in the quarter due to generic competition

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Novartis
2Q Revenues: $12.2 billion (-2%)
2Q Earnings: $2.0 billion (+10%)
YTD Revenues: $23.8 billion (-1%)
YTD Earnings: $3.6 billion (-5%)
Comments: Innovative Medicines sales were $8.3 billion (-1%) in the second quarter, with growth driven by Cosentyx ($490 million, +90% cc), Entresto ($110 million +240% cc), Promacta/Revolade ($210 million, +35% cc), Tafinlar + Mekinist (USD 216 million, +28% cc), Jakavi ($186 million, +32% cc), and Gilenya $837 million, +5% cc). Generic competition had a negative impact of 4 percentage points and pricing had a negative impact of 2 percentage points, both largely due to Gleevec/Glivec generics in Europe and the U.S. Sandoz sales were $2.5 billion, down 5% due to price erosion, mainly in the U.S.  Sales in the U.S. declined 15% (cc), mainly due to pricing pressure in retail generics and prior year launch timing. Net sales across Europe and the rest of the world grew 3% (cc). Alcon sales were $1.5 billion (+1%) in the second quarter. Surgical sales grew 3% and Vision Care sales grew 2%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters